Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod Tyramine Interaction Study
NCT03694119Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Jul 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ozanimod in multiple sclerosis (MS) and ulcerative colitis (UC) (3 arms), sponsored by Celgene Corporation. Primary endpoint: Cardiovascular (Pressor Response to Tyramine) at Day 49. Started Jul 2018; status: completed.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03694119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03694119.